A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

ClinicalTrials.gov ID: NCT03662542

Public ClinicalTrials.gov record NCT03662542. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the clinical efficacy and safety of combination therapy with guselkumab and golimumab in participants with moderately to severely active ulcerative colitis (UC).

Study identification

NCT ID: NCT03662542
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Janssen Research & Development, LLC; Industry
Enrollment: 214 participants

Conditions and interventions

Conditions

Colitis, Ulcerative

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 20, 2018 (Actual)
Primary completion: Dec 1, 2020 (Actual)
Completion: Nov 15, 2021 (Actual)
Last update posted: Dec 12, 2023

2018 – 2021

United States locations

U.S. sites: 14
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
Precision Research Institute	San Diego	California	92114	—
Peak Gastroenterology Associates	Colorado Springs	Colorado	80907	—
GCP Clinical Research	Tampa	Florida	33609	—
Gastrointestinal Specialists of Georgia	Marietta	Georgia	30060	—
Indiana University	Indianapolis	Indiana	46202	—
Chevy Chase Clinical Research	Chevy Chase	Maryland	20815	—
Woodholme Gastroenterology	Glen Burnie	Maryland	21061	—
Sierra Clinical Research	Las Vegas	Nevada	89106	—
The University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	27599	—
Fargo Gastroenterology Clinic, PC	Fargo	North Dakota	58103	—
Texas Digestive Disease Consultants	Southlake	Texas	76092	—
Gastroenterology Associates of Tidewater	Chesapeake	Virginia	23320	—
Virginia Mason	Seattle	Washington	98101	—
Washington Gastroenterology, PLLC	Tacoma	Washington	98405	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 68 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03662542, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 12, 2023 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03662542 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →